Incidence and risk factors of hospitalization for bronchiolitis in preterm children: A retrospective longitudinal study in Italy

BMC Pediatrics

Volumn 9, Issue , 2009, Pages 56-

  Pezzotti, Patrizio ^a   Mantovani, Jessica ^a   Benincori, Nicoletta ^b   Mucchino, Eleonora ^c   Di Lallo, Domenico ^a  

^a Public Health Agency Lazio Region   (Italy)

^b Neonatology and Paediatric unit   (Italy)

^c San Giuseppe Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

AGE; APGAR SCORE; ARTICLE; BRONCHIOLITIS; CHILD; CHILD HOSPITALIZATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; FEMALE; GENDER; GESTATIONAL AGE; HUMAN; INCIDENCE; INFANT; ITALY; LONGITUDINAL STUDY; LOW BIRTH WEIGHT; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; MATERNAL AGE; PREMATURITY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 70349881502     PISSN: None     EISSN: 14712431     Source Type: Journal    
DOI: 10.1186/1471-2431-9-56     Document Type: Article

References (25)

1. Lozano JM. Bronchiolitis. Clinical Evidence 2004, 11:360-374.
2. Smyth RL, Openshaw PJ. Bronchiolitis. Lancet 2006, 368:312-22. 10.1016/S0140-6736(06)69077-6, 16860701.
3. Godfrey S. Bronchiolitis and asthma in infancy and early childhood. Thorax 1996, 51:560-4.
4. Langley J, . for the Infectious Diseases and Immunization Committee of the Canadian Pediatric Society Use of palivizumab in children with congenital disease. Paediatr Child Health 2003, 8:631-33.
5. Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr 2003, 143:S112-7. 10.1067/S0022-3476(03)00508-0, 14615709.
6. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 2003, 143:S118-26. 10.1067/S0022-3476(03)00511-0, 14615710.
7. Henrickson KJ, Hoover S, Kehl KS, Hua W. National disease burden of respiratory viruses detected in children by polymerase chain reaction. Pediatr Infect Dis J 2004, 23:S11-8. 10.1097/01.inf.0000108188.37237.48, 14730265.
8. Impact-RSV study group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537.
9. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Connor EM, Sondheimer HM, . Cardiac Synagis Study Group Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003, 143:532-540. 10.1067/S0022-3476(03)00454-2, 14571236.
10. American Academy of Pediatrics, Committee of infectious Diseases and Committee on Fetus and Newborn Prevention of respiratory syncitial virus infections: indications for the use of palivizumab and update on the use of VRSIGIV. Pediatrics 1998, 102:1211-1216. 10.1542/peds.102.5.1211, 9794957.
11. American Academy of Pediatrics, Committee of infectious Diseases and Committee on Fetus and Newborn Revised indications for the use of palivizumab and respiratory syncitial virus immune globulin intravenous for the prevention of respiratory syncitial virus infections. Pediatrics 2003, 112:1442-1446. 10.1542/peds.112.6.1442, 14654627.
12. Società Italiana di Neonatologia Raccomandazioni della Società Italiana di Neonatologia per la prevenzione delle malattie da virus respiratorio sinciziale (VRS). Aggiornamento 2004, 1:1-11.
13. Oh PI, Lanctjt KL, Yoon A, Lee DS, Paes BA, Simmons BS, Parison D, Manzi P, . Composs Investigators Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J 2002, 21:512-8. 10.1097/00006454-200206000-00007, 12182374.
14. Singleton R, Dooley L, Bruden D, Raelson S, Butler JC. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants. Pediatr Infect Dis J 2003, 22:540-545. 10.1097/00006454-200306000-00010, 12799511.
15. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, . IRIS Study Group Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 2003, 22:823-827. 10.1097/01.inf.0000086403.50417.7c, 14506376.
16. Henckel E, Luthander J, Berggren E, Kapadia H, Naver L, Norman M, Bennet R, Eriksson M. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002. Pediatr Infect Dis J 2004, 23:27-31. 10.1097/01.inf.0000105106.93562.d3, 14743042.
17. Grimaldi M, Gouyon B, Sagot P, Quantin C, Huet F, Gouyon JB, . Burgundy Perinatal Network Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia. Pediatr Pulmonol 2007, 42:189-192. 10.1002/ppul.20503, 17243184.
18. Agostini D, Chiappa G, Gasperini AM, Stefanelli P. The quality of the data on the certificate of delivery care. Epidemiol Prev 1996, 20:76-9.
19. Di Paolo AM, Fumu L, Minelli L, Di Renzo GC. The birth certificate as an instrument for pregnancy. Minerva Ginecol 2008, 60:339-344.
20. Di Napoli A, Pezzotti P, Di Lallo D, Tancioni V, Papini P, Guasticchi G. Determinants of hospitalization in a cohort of chronic dialysis patients in central Italy. J Nephrol 2005, 18:21-29.
21. Calvani M, Di Lallo D, Polo A, Spinelli A, Zappala D, Zicari M. Hospitalizations for pediatric anaphylaxis. Int J Immunopathol Pharmacol 2008, 21:977-983.
22. Dal Maso L, Braga C, Franceschi S. Methodology used for "software for automated linkage in Italy" (SALI). J Biomed Inform 2001, 34:387-395. 10.1006/jbin.2002.1036, 12198758.
23. Heikkinen T, Valkonen H, Lehtonen L, Vainionpaa R, Ruuskanen O. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch Dis Child Fetal Neonatal Ed 2005, 90:F64-F68. 10.1136/adc.2003.029710, 1721807, 15613580.
24. Grimwood K, Cohet C, Rich FJ, Cheng S, Wood C, Redshaw N, Cunningham CW, Pearce N, Kirman JR. Risk factors for respiratory syncytial virus bronchiolitis hospital admission in New Zealand. Epidemiol Infect 2008, 136:1333-41. 10.1017/S0950268807000180, 18177522.
25. Fewell Z, Davey Smith G, Sterne JA. The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. Am J Epidemiol 2007, 166:646-55. 10.1093/aje/kwm165, 17615092.